Contact us
Young GI
Patients
Industry
Press
myUEG Community
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Annual Report
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Attendance
Fees
Hotel
Venue
Programme
UEG Week on-demand
Abstracts
Postgraduate Teaching
Nurse Programme
Industry Programme
Industry Exhibition
Industry Symposia
Acknowledgements
CME Accreditation
Future UEG Weeks
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass on Chronic Pancreatitis
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Research
To landing page
Support
Horizon Europe Support
Research Prize
Research Fellowship
Research Webinars
Advocacy
White Book
Position Papers
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
Guideline development framework
Get Funding
Get Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Manifesto on Digestive Health
Core Positions
Stakeholder Collaboration
White Book
Digestive Health Month
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Application Support
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Education articles
Contact us
Young GI
Patients
Industry
Press
Author
Marla C. Dubinsky
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Marla C. Dubinsky
et al.
Most Patients with Ulcerative Colitis ‘Can’t Wait’: The Impact and Clinical Assessment of Bowel Urgency (PeerVoice)
Marla C. Dubinsky
et al.
JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)
Marla C. Dubinsky
et al.
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
BIOMARKERS AND BOWEL URGENCY IN RESPONSE TO MIRIKIZUMAB FOR ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
Marla C. Dubinsky
et al.
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB
Marla C. Dubinsky
et al.
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Marla C. Dubinsky
CLINICAL AND HEALTH OUTCOMES ASSOCIATED WITH TREATMENT SEQUENCES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
Marla C. Dubinsky
et al.
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
Can we prevent IBD by targeting the intestinal microbiota?
Marla C. Dubinsky
Effectively moving forward: Shining without diminishing
Marla C. Dubinsky
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Marla C. Dubinsky
et al.
COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Targeting inflammation to improve long-term outcomes in UC (Bristol Myers Squibb)
Marla C. Dubinsky
et al.
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
Marla C. Dubinsky
et al.
Item 1 - 20 / 35
1
2